司法部于周二表示，两名印度国民在佛罗里达州联邦法院被起诉，罪名是涉嫌共谋从中国走私假冒的“欧西匹克”（Ozempic）。据称，甚至在2023年美国食品药品监督管理局（FDA）查获部分假冒减肥药并向公众发出警告之后，该走私计划仍在继续。
Two Indian nationals have been charged in federal court in Florida with an alleged conspiracy to smuggle counterfeit Ozempic from China in a scheme that purportedly continued even after the Food and Drug Administration seized some of the fake weight-loss drugs in 2023 and warned the public about it, the Department of Justice said Tuesday. One of the men, 33-year-old Swapnadip Roy, was extradited from Italy and made his initial appearance in U.S. District Court in Tampa, Florida, on Tuesday.
其中一名嫌疑人是33岁的斯瓦普纳迪普·罗伊（Swapnadip Roy），他从意大利被引渡，并于周二在佛罗里达州坦帕市的美国联邦地区法院首次出庭。
Roy and his alleged co-conspirator, Vicky Ramancha, 37, are charged in an indictment with one count of conspiracy to commit smuggling and to defraud the U.S., three counts of smuggling, and two counts of selling counterfeit drugs and holding counterfeit drugs for sale.
罗伊与其同谋、37岁的维基·拉曼恰（Vicky Ramancha）在起诉书中被控一项共谋走私及欺诈美国的罪名、三项走私罪以及两项销售假药及持有假药以供销售的罪名。如果罪名成立，两人最高将面临71年的监禁。拉曼恰目前仍然在逃。
If convicted, they both face a maximum sentence of 71 years in prison. Ramancha remains at large. Court documents state Roy and Ramancha, starting in July 2023 and continuing to the following April, allegedly obtained counterfeit Ozempic from unauthorized sources in China.
法院文件显示，罗伊和拉曼恰涉嫌自2023年7月起至次年4月，从中国的未经授权渠道获取假冒的“欧西匹克”。这款热门药物由诺和公司（Novo，近期已从“诺和诺德”更名）制造。
The popular drug is made by Novo, which recently rebranded from its name Novo Nordisk. The material they and their co-conspirators allegedly distributed "included counterfeit packaging, package inserts, pen labels, and needles meant to deceive downstream customers into believing they were purchasing authentic Ozempic authorized by the manufacturer," DOJ said.
司法部表示，他们及其同谋分发的物质“包括假冒的包装、说明书、注射笔标签和针头，旨在欺骗下游客户，使其相信他们购买的是由制造商授权的正品欧西匹克”。
The case comes as the use of so-called GLP-1 medications such as Ozempic for weight loss has become increasingly popular in the U.S.
此案出台之际，在美国，将被称为GLP-1的药物（如Ozempic）用于减重正变得日益流行。
In July, Gallup reported that the percentage of U.S. adults who take GLP-1 medications for weight loss purposes rose to 11% in 2026, compared to 3% in 2024.
盖洛普（Gallup）于7月发布报告称，为减重目的而服用GLP-1药物的美国成年人比例在2026年上升至11%，而2024年这一比例为3%。
"And 15% report having used the medicine for weight loss at some point, an increase of nine percentage points" over 2024, Gallup noted.
盖洛普指出：“还有15%的人表示曾在某个时期使用过该药物进行减重，比2024年增加了9个百分点。”
"Counterfeit prescription drugs — especially common ones — threaten the health and safety of every American who depends on the integrity of our pharmaceutical supply," Assistant Attorney General A. Tysen Duva of the DOJ's Criminal Division said in a statement Tuesday.
美国司法部刑事司助理司法部长A·泰森·杜瓦周二在一份声明中表示：“假冒处方药——尤其是常见的药物——威胁着每一位依赖我国药品供应链完整性的美国人的健康与安全。”
"These defendants allegedly exploited people's health to pay themselves.
杜瓦表示：“这些被告据称利用人们的健康来为自己牟利。我们将继续追究任何试图用假冒药品欺骗美国消费者的行为。”
We will keep pursuing anyone who seeks to deceive American consumers with counterfeit drugs," Duva said.